Format

Send to

Choose Destination
Biochem Pharmacol. 2017 Mar 15;128:1-11. doi: 10.1016/j.bcp.2016.11.014. Epub 2016 Nov 24.

Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Author information

1
Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States; Center for Drug Discovery, Northeastern University, Boston, MA 02115, United States.
2
Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States; Center for Drug Discovery, Northeastern University, Boston, MA 02115, United States; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, United States. Electronic address: a.makriyannis@neu.edu.

Abstract

The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design. The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications. Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clinical utility due to their propensity to incite on-target adverse events. Chemically distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways. In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists. We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses. The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs.

KEYWORDS:

Biased agonism; Drug discovery; Effector pathways; GPCR

PMID:
27890725
PMCID:
PMC5470118
DOI:
10.1016/j.bcp.2016.11.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center